Navigation Links
Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
Date:5/29/2009

PITTSBURGH, May 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Montelukast Sodium Tablets, 10 mg (base).

Montelukast Sodium Tablets are the generic version of Merck and Co.'s Singulair(R), which had total U.S. sales of approximately $2.6 billion for the 12 months ending March 31 for the same strength, according to IMS Health. This product is indicated for asthma and allergy treatment.

Currently, Mylan has 117 ANDAs pending FDA approval representing $82.1 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, which represent $16.7 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
2. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
3. Mylan Confirms Four First-to-File Challenges
4. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
7. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
8. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
9. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
10. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
11. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... will deliver a talk on its first-in-class technologies for tissue stem cell counting ... on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. ...
(Date:4/27/2016)... ... ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” Gardner was ... since 1987. Since then, he has served in a number of key leadership positions ... the program and exposition committees. In his professional career, Dr. Gardner is the director ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... Clark has joined the company as an Expert Consultant. Mr. Clark was ... collaborations and managing the development of small molecule monographs based on analytical methods. ...
(Date:4/27/2016)... , April 27, 2016 MedDay, ... disorders, today announces the appointment of Catherine Moukheibir as Chairman ... MedDay,s previous Chairman, Jean Jacques Garaud , who contributed ... change is effective immediately. Catherine started her career ... and London .  She held ...
Breaking Biology Technology:
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/17/2016)... March 17, 2016 ABI Research, the ... the global biometrics market will reach more than ... increase from 2015. Consumer electronics, particularly smartphones, continue ... sensors anticipated to reach two billion shipments by ... Dimitrios Pavlakis , Research Analyst at ABI Research. ...
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
Breaking Biology News(10 mins):